Filtered By:
Condition: Polycystic Ovary Syndrome
Drug: Fortamet
This page shows you your search results in order of date.
Order by Relevance | Date
Total 398 results found since Jan 2013.
SPIOMET4HEALTH —efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome: study protocol for a multicentre, randomised, double-blind, placebo-controlled, fo ur-arm, parallel-group, phase II clinical trial
DiscussionThe present study will be the first to evaluate —in a randomised, double-blind, placebo-controlled way—the efficacy, tolerability and safety of SPIOMET treatment for early PCOS, on top of a lifestyle intervention.Trial registrationEudraCT 2021 –003177-58. Registered on 22 December 2021.https://www.clinicaltrialsregister.eu/ctr-search/search?query=%092021-003177-58.
Source: Trials - September 15, 2023 Category: Research Source Type: clinical trials
Quantitative risk-benefit profiles of oral contraceptives, insulin sensitizers and antiandrogens for women with polycystic ovary syndrome: A model-based meta-analysis
This study aimed to quantitatively evaluate the effects of the aforementioned medications and to compare their risk-benefit profiles. Randomized controlled trials published until 14th March 2022 were searched in PubMed and Embase. A model-based meta-analysis was developed to examine the time-effect profiles of each medication. The maximal percentage change of the effect (Emax) and time to achieve half of Emax (T50) were estimated. Primary outcomes included menstruation, hirsutism score, free androgen index (FAI), body mass index (BMI), insulin sensitivity, and lipid profiles. Overall, 200 studies (9,685 patients and 385 ar...
Source: European Journal of Pharmaceutical Sciences - September 4, 2023 Category: Drugs & Pharmacology Authors: Zhe Tang Jing Guan Jue-Hui Mao Lu Han Juan-Juan Zhang Rui Chen Zheng Jiao Source Type: research
Quantitative risk-benefit profiles of oral contraceptives, insulin sensitizers and antiandrogens for women with polycystic ovary syndrome: a model-based meta-analysis
This study aimed to quantitatively evaluate the effects of the aforementioned medications and to compare their risk-benefit profiles. Randomized controlled trials published until 14th March, 2022 were searched in PubMed and Embase. A model-based meta-analysis was developed to examine the time-effect profiles of each medication. The maximal percentage change of the effect (Emax) and time to achieve half of Emax (T50) were estimated. Primary outcomes included menstruation, hirsutism score, free androgen index (FAI), body mass index (BMI), insulin sensitivity, and lipid profiles. Overall, 200 studies (9,685 patients and 385 a...
Source: European Journal of Pharmaceutical Sciences - September 4, 2023 Category: Drugs & Pharmacology Authors: Zhe Tang Jing Guan Jue-Hui Mao Lu Han Juan-Juan Zhang Rui Chen Zheng Jiao Source Type: research
Non-coding RNA genes modulate PI3K/AKT signaling pathway in polycystic ovary syndrome
CONCLUSIONS: miRNA486 and miRNA483 downregulation may contribute to the etiology of PCOS, influence glucose metabolism, and result in IR in PCOS. Metformin's upregulation of those miRNAs affects glucose metabolism by controlling the expression of GLUT4, ameliorates PCOS-related insulin resistance, and improves PCOS-related hormonal imbalance by controlling the PI3K/AKT signaling pathway.PMID:37620736 | DOI:10.1007/s11033-023-08604-0
Source: Molecular Biology Reports - August 24, 2023 Category: Molecular Biology Authors: Heba S Omar Osama Ahmed Ibrahim Maha Gomaa Sayed Eman Mohammed Faruk Hanan Fouad Miriam Safwat Source Type: research
Polycystic ovary syndrome and thyroid disorder: a comprehensive narrative review of the literature
ConclusionPCOS and thyroid disorders are closely related, and their coexistence may identify patients with a higher reproductive and metabolic risk. Regular screening for thyroid function and thyroid-specific autoantibodies in women with PCOS, particularly before and during pregnancy, is highly recommended.
Source: Frontiers in Endocrinology - August 11, 2023 Category: Endocrinology Source Type: research
Metformin and combined oral contraceptive pills in the management of polycystic ovary syndrome: a systematic review and meta-analysis
CONCLUSIONS: The choice of metformin or COCP treatment should be based on symptoms, noting that there are some biochemical benefits from combination treatment, targeting both major endocrine disturbances seen in PCOS; hyperinsulinemia and hyperandrogenism.PMID:37554096 | DOI:10.1210/clinem/dgad465
Source: The Journal of Clinical Endocrinology and Metabolism - August 9, 2023 Category: Endocrinology Authors: Johanna Melin Maria Forslund Simon Alesi Terhi Piltonen Daniela Romualdi Poli Mara Spritzer Chau Thien Tay Alexia Pena Selma Feldman Witchel Aya Mousa Helena Teede Source Type: research
The impact of metformin with or without lifestyle modification versus placebo on polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials
CONCLUSIONS: Metformin should be considered as an efficacious adjunct to lifestyle interventions in adults with PCOS, especially for those with a higher BMI, to improve weight loss, insulin resistance and lipids.PMID:37536294 | DOI:10.1093/ejendo/lvad098
Source: European Journal of Endocrinology - August 3, 2023 Category: Endocrinology Authors: Johanna Melin Maria Forslund Simon Alesi Terhi Piltonen Daniela Romualdi Poli Mara Spritzer Chau Thien Tay Alexia Pena Selma Feldman Witchel Aya Mousa Helena Teede Source Type: research
Women with PCOS who undergo IVF: a comprehensive review of therapeutic strategies for successful outcomes
Reprod Biol Endocrinol. 2023 Aug 1;21(1):70. doi: 10.1186/s12958-023-01120-7.ABSTRACTPolycystic ovarian syndrome (PCOS) is a widespread syndrome that poses unique challenges and constraints to the field of assisted reproductive technology. This condition is the most common cause of anovulation among infertile couples. Debate exists over the best therapeutic course of action when patients with PCOS proceed to IVF. In this review, we evaluate the best-performing and safest methods of IVF preparation, ovarian stimulation, trigger method for maturation of stimulated egg growth, and planning for embryo transfer. Pre-IVF conside...
Source: Reproductive Biology - August 1, 2023 Category: Reproduction Medicine Authors: Alexander M Kotlyar David B Seifer Source Type: research
Statins for women with polycystic ovary syndrome not actively trying to conceive
CONCLUSIONS: The evidence for all main outcomes of this review was of very low certainty. Due to the limited evidence, we are uncertain if statins compared with placebo, or statins plus metformin compared with metformin alone, improve resumption of menstrual regularity. The trial evaluating statin plus OCP versus OCP alone reported neither of our primary outcomes. No other studies reported resumption of spontaneous ovulation. We are uncertain if statins improve hirsutism, acne severity, or testosterone. All trials that measured adverse events reported no significant differences between the groups.PMID:37462232 | PMC:PMC103...
Source: Cochrane Database of Systematic Reviews - July 18, 2023 Category: General Medicine Authors: Ting Xiong Eloise Fraison Eleni Kolibianaki Michael F Costello Christos Venetis Elena B Kostova Source Type: research
Unraveling the Interplay between Nonalcoholic Fatty Liver Disease and Polycystic Ovary Syndrome in Adolescents: Pathogenesis, Prevalence, and Management Strategies
CONCLUSIONS A meticulous approach to the prevention, detection, and treatment of NAFLD in adolescents with PCOS is paramount to mitigate further complications. The study underlines the need for ongoing research to refine our understanding and management of these interconnected metabolic disorders.PMID:37455412 | DOI:10.12659/MSM.940398
Source: Medical Science Monitor - July 17, 2023 Category: Research Authors: Kinga P ółkośnik Agnieszka Łebkowska Irina Kowalska Dariusz M Lebensztejn Source Type: research
Position paper of the Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), and the Italian Study Group of Diabetes in pregnancy: Metformin use in pregnancy
ConclusionsMetformin may represent a therapeutic option in selected women with obesity, PCOS, GDM, T2DM, and in women undergoing ART. However, more research is required specifically on the long-term effects of in utero exposition to metformin.
Source: Acta Diabetologica - July 4, 2023 Category: Endocrinology Source Type: research
Metformin inhibits ovarian granular cell pyroptosis through the miR-670-3p/NOX2/ROS pathway
This study aimed to investigate the impact of metformin on OGC pyroptosis and the underlying mechanisms. The results showed that treating a human granulosa-like tumor cell line (KGN) with metformin significantly decreased LPS-induced expression of miR-670-3p, NOX2, NLRP3, ASC, cleaved caspase-1, and GSDMD-N. Cellular caspase-1 activity; ROS production; oxidative stress; and the secretion of IL-1β, IL-6, IL-18, and TNF-α were also diminished. These effects were amplified by adding N-acetyl-L-cysteine (NAC), a pharmacological inhibitor of ROS. In contrast, metformin's anti-pyroptosis and anti-inflammatory effects were robu...
Source: Aging - May 27, 2023 Category: Biomedical Science Authors: Li-Hua Zhou Hui Zou Jia-Yuan Hao Yong Huang Jia-Nan Zhang Xiao-Hong Xu Juan Li Source Type: research
